John Gosserand, MD
Hepatology · Alexandria, LANPI 1356371231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 1,044 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 24.1% of the total.
Across 1,044 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- QOL Medical, LLC$729
- Bristol Myers Squibb$609
- plus $4K from 29 others
What the payments were for
- Food & beverage$14,50799%
- Education$1331%
- Gifts$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 265 | $3,542 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 257 | $3,308 |
| Johnson & Johnson | 103 | $1,545 |
| Takeda Pharmaceuticals U.S.A., Inc. | 83 | $1,231 |
| QOL Medical, LLC | 44 | $729 |
| Bristol Myers Squibb | 75 | $609 |
| Pfizer | 22 | $443 |
| Ardelyx, Inc. | 24 | $423 |
| Braintree Laboratories, Inc. | 17 | $313 |
| Gilead | 23 | $308 |
| Intercept Pharmaceuticals, Inc. | 19 | $277 |
| Ironwood Pharmaceuticals, Inc | 14 | $226 |
| Nestle Healthcare Nutrition Inc. | 11 | $204 |
| Redhill Biopharma Inc. | 12 | $198 |
| Merck | 12 | $184 |
| Lilly USA, LLC | 10 | $183 |
| Ferring Pharmaceuticals Inc. | 9 | $142 |
| Ipsen Biopharmaceuticals, Inc | 7 | $139 |
| Phathom Pharmaceuticals, Inc. | 7 | $115 |
| Sanofi | 4 | $112 |
| Madrigal Pharmaceuticals | 5 | $90 |
| Evoke Pharma, Inc. | 5 | $79 |
| Aimmune Therapeutics, Inc. | 2 | $68 |
| Pentax Of America, Inc. | 1 | $49 |
| UCB, Inc. | 2 | $30 |
| Amgen | 1 | $25 |
| Boston Scientific | 2 | $25 |
| Boehringer Ingelheim | 1 | $19 |
| Organon | 1 | $19 |
| Sandoz | 1 | $16 |
| Capsovision, Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Echosens North America, Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
Too few hepatology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $335,627 |
| Skyrizi On-BodyRisankizumab-Rzaa | 15 | $311,220 |
| LinzessLinaclotide | 156 | $106,176 |
| CreonLipase/Protease/Amylase | 27 | $90,118 |
| XifaxanRifaximin | 29 | $75,678 |
| ZenpepLipase/Protease/Amylase | 11 | $42,876 |
| TrulancePlecanatide | 55 | $38,922 |
| VemlidyTenofovir Alafenamide | 12 | $16,365 |
| Budesonide ErBudesonide | 15 | $14,959 |
| Dexlansoprazole DrDexlansoprazole | 40 | $13,802 |
| MovantikNaloxegol Oxalate | 18 | $10,904 |
| Colestipol Hcl | 152 | $8,216 |
| Sucralfate | 120 | $7,556 |
| Budesonide DrBudesonide | 38 | $7,324 |
| MotofenDifenoxin Hcl/Atropine Sulfate | 12 | $7,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,545 | $335,62713 claims |
| AbbVieLinzess, Creon | $3,542 | $196,294183 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $3,308 | $114,60084 claims |
| Aimmune Therapeutics, Inc.Zenpep | $68 | $42,87611 claims |
| GileadVemlidy | $308 | $16,36512 claims |
| Redhill Biopharma Inc.Movantik | $198 | $10,90418 claims |
| Braintree Laboratories, Inc.Motofen | $313 | $7,25112 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $142 | $3,09619 claims |
| SandozLansoprazole | $16 | $53228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other hepatology in Alexandria
- Manohar MaramrajAlexandria$224
- George TherapondosNew Orleans$365K
- Shobha JoshiNew Orleans$169K
- Nigel GirgrahNew Orleans$97K
- Peng-Sheng TingNew Orleans$6K
- Molly DelkNew Orleans$4K
- Mariana ZapataNew Orleans$375
- Thomas ParambilNew Orleans$16
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.